Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

4 Apr 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24699304
DOI: 10.1038/leu.2014.119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsPMID 24699304Read ↗

Advances Toward Lsd1 Inhibitors for Cancer TherapySemantic proximity Read ↗

Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid LeukemiaSemantic proximity Read ↗

Inhibitors of LSD1 as a potential therapy for acute myeloid leukemiaSemantic proximity Read ↗

A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancersSemantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AMLSemantic proximity Read ↗

Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors.Semantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AMLSemantic proximity Read ↗

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsSemantic proximity Read ↗

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaSemantic proximity Read ↗

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutationsSemantic proximity Read ↗

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to DateSemantic proximity Read ↗

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.